Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | JAK1 V658F JAK1 L929Q |
| Therapy | Ruxolitinib |
| Indication/Tumor Type | hematologic cancer |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| JAK1 V658F JAK1 L929Q | hematologic cancer | predicted - resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, a cell line expressing JAK1 V658F and L929Q was moderately resistant to Jakafi (ruxolitinib) in culture (PMID: 39091915). | 39091915 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39091915) | Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms. | Full reference... |